Earnings Feed
Start Free
Home/Filings/4/0001871714-26-000001
4//SEC Filing

Giordano Christopher Thomas 4

Accession 0001871714-26-000001

CIK 0000034956other
View on SEC.govCompany Profile

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 9:37 PM ET

Size

13.9 KB

Accession

0001871714-26-000001

Insider Transaction Report

Form 4
Period: 2026-01-09
TENAX THERAPEUTICS, INC.TENX
Giordano Christopher Thomas
DirectorCEO
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-01-09+450,000→ 450,000 total
    Exercise: $13.30Exp: 2036-01-09→ Common Stock (450,000 underlying)
Holdings

  • Common Stock

    2,605

  • Stock Option (right to buy)

    [F2]
    Exercise: $3152.00Exp: 2031-07-06→ Common Stock (157 underlying)
    157

  • Stock Option (right to buy)

    [F3]
    Exercise: $992.00Exp: 2032-06-09→ Common Stock (125 underlying)
    125

  • Stock Option (right to buy)

    [F4]
    Exercise: $3.55Exp: 2034-05-17→ Common Stock (437 underlying)
    437

  • Stock Option (right to buy)

    Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (1,250,000 underlying)
    1,250,000

  • Stock Option (right to buy)

    [F5]
    Exercise: $5.89Exp: 2035-05-16→ Common Stock (1,400,000 underlying)
    1,400,000
Footnotes (5)
  • [F1]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
  • [F2]The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
  • [F3]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
  • [F4]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
  • [F5]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact|2026-01-13

Documents

1 file

Issuer

TENAX THERAPEUTICS, INC.

CIK 0000034956

→
Entity typeother

Related Parties

1
  • filerCIK 0001871714

Filing Metadata

Form type
4
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 9:37 PM ET
Size
13.9 KB
View on SEC.gov